# AusperBio Raises $120M Series C for Hepatitis B Oligonucleotide Therapy

AusperBio Therapeutics has raised $120 million in series C financing. The company will use the funds to advance its oligonucleotide therapy for chronic hepatitis B through phase 3 testing. The goal is to reach commercialization. The announcement was reported by Fierce Biotech.

Chronic hepatitis B is a major global health concern. Current treatments often require long-term use. Oligonucleotide therapies target viral RNA. This approach may offer a new way to treat the infection. The funding supports late-stage development of a novel therapy. It also reflects growing interest in RNA-based medicines for infectious diseases.

Source: [original report](https://www.fiercebiotech.com/biotech/ausperbio-adds-120m-advance-hepatitis-b-therapy-through-ph3-and-commercialization)